Why BPD Has No Cure Yet: The Multifactorial Biology

Bronchopulmonary dysplasia (BPD) resists single-target treatment because it is not one disease but a convergence of at least five distinct pathogenic mechanisms operating simultaneously in the most vulnerable premature lungs. Infants born at 22–28 weeks of gestation face disruption of the saccular stage of lung morphogenesis—the precise developmental window when alveolarization and pulmonary microvascular formation are underway. Arrest at this stage produces the histopathological hallmarks of BPD: impaired distal lung alveolarization and dysregulated pulmonary microvascular development, with arrested capillary growth contributing to impaired gas exchange and elevated pulmonary vascular resistance.

The five core pathogenic mechanisms identified across the literature are oxidative stress from hyperoxia and mechanical ventilation, inflammatory dysregulation driven by cytokines including IL-1β and TGF-β, disrupted growth factor signaling across the VEGF/PDGF/FGF/IGF-1/WNT axes, extracellular matrix remodeling including dysregulation of the matricellular protein SPARC, and non-coding RNA dysregulation involving the miR-34a/PDGFRα axis, lncRNA H19/MAPK pathway, and miR-17-92 cluster. The “BPD trio” framing—dysregulated PDGF, VEGF, and TGF signaling collectively driving inflammation, ECM remodeling, and vascular impairment—captures the interdependence that makes single-agent strategies insufficient.

Excess TGF-β signaling acts as an upstream activator of canonical WNT signaling and an inhibitor of PPARγ, collectively impeding alveolar maturation. Persistent high-level canonical WNT pathway activity at the canalicular stage disrupts pulmonary maturation at both saccular and alveolar stages. According to WHO global preterm birth data, preterm birth complications are the leading cause of death among children under five—context that underscores the urgency of the BPD pipeline. This biological complexity explains why existing pharmacotherapies—corticosteroids, caffeine, diuretics, vitamin A, and inhaled nitric oxide—are characterized in the literature as incapable of single-handedly altering BPD natural history.

MSC Therapy: From Phase I Safety to Phase II Efficacy Questions

Mesenchymal stem/stromal cell (MSC) therapy is the single most prominently represented therapeutic modality in the BPD literature, appearing across more than 20 papers, and it is the only BPD intervention with completed randomized controlled trial data in preterm infants. The mechanistic premise—consistently supported across preclinical and clinical evidence—is that MSCs act via paracrine rather than engraftment mechanisms: secreted trophic and immunomodulatory factors, including extracellular vesicles and conditioned media, mediate lung protection and alveolar repair without direct cellular integration into lung tissue.

The Samsung Medical Center phase I trial established safety and feasibility of intratracheal MSC transplantation at a dose of 1×10⁷ cells/kg in preterm infants, providing the rationale for the subsequent phase II study. The phase II double-blind RCT enrolled 66 infants (33 MSC, 33 placebo) at gestational ages of 23–28 weeks. The trial demonstrated statistically significant reductions in tracheal aspirate inflammatory cytokines with MSC therapy, but the composite primary endpoint of death or severe/moderate BPD did not reach statistical significance. This gap between biomarker improvement and clinical outcome is the central unresolved question in MSC translation for BPD.

“MSC therapy demonstrated statistically significant reductions in tracheal aspirate inflammatory cytokines in a phase II RCT—yet the composite endpoint of death or severe/moderate BPD did not reach statistical significance, leaving the efficacy question open.”

MSC sources evaluated in the literature include bone marrow-derived MSCs (BM-MSCs), human umbilical cord tissue (Wharton’s jelly) MSCs (hUC-MSCs), umbilical cord blood mononuclear cells, and placenta-derived stem cells. Delivery routes span intratracheal, intravenous, intraperitoneal, and intranasal approaches. A case report from National Taiwan University Children’s Hospital (2018) describes intratracheal delivery of maternal BM-MSCs in a 10-month-old infant with BPD superimposed on adenovirus-ARDS, resulting in ECMO removal 25 days post-administration—described as the first published human report of BM-MSC reversal of this severity. Short tandem repeat analysis confirmed the absence of maternal cells in bronchial washings, directly supporting the paracrine mechanism hypothesis.

MSC-derived conditioned media (CM) and exosomes have emerged as cell-free alternatives to direct transplantation. Evidence from Children’s Hospital Boston/Harvard Medical School (2012) demonstrated that a single intravenous dose of MSC-derived CM reversed hyperoxia-induced BPD and pulmonary hypertension in a rodent model, normalizing alveolar injury and blood vessel density. A Harvard Medical School review (2019) frames MSC-derived exosomes (MEx) as a “compelling therapeutic alternative” to MSC transplantation for both BPD and BPD-associated pulmonary hypertension, citing manufacturing standardization, cryostability, and avoidance of cell-viability attrition as key advantages. Research published in journals indexed by NIH PubMed has increasingly documented the exosome mechanism in neonatal lung injury models.

IGF-1 Supplementation and TGF-β Antagonism: The Growth Factor Frontier

Two distinct growth factor strategies represent the most patent-active and preclinically advanced non-cellular approaches in the BPD pipeline: recombinant human IGF-1 supplementation addressing a physiological deficit in preterm infants, and TGF-β antagonism targeting the pathway most directly implicated in arrested alveolar development. Both remain in preclinical or patent-stage development with no completed clinical trial data specifically in BPD.

IGF-1: Replacing a Physiological Deficit

IGF-1 is markedly decreased in normal preterm infants, and this postnatal deficiency is framed in the literature as a mechanistic vulnerability to BPD. Preclinical evidence from Arizona State University demonstrated that postnatal rhIGF-1/BP3 (recombinant human IGF-1 complexed with binding peptide 3) treatment preserved lung growth and prevented pulmonary hypertension across three distinct rodent BPD models: chorioamnionitis-induced via intraamniotic endotoxin, preeclampsia-simulated via sFlt-1, and hyperoxia. The breadth of efficacy across etiologically distinct models strengthens the argument for IGF-1 deficiency as a convergent vulnerability rather than a model-specific artifact. Stanford University researchers have independently identified IGF-1 axis disruption alongside WNT and VEGF signaling as mechanistic targets for novel lung growth-enhancing strategies in neonatal chronic lung disease.

TGF-β Antagonism: The Most Patent-Dense IP Position

The General Hospital Corporation (Massachusetts General Hospital) holds the most commercially defined IP position in the entire retrieved BPD dataset—a substantial family of active patents on TGF-β antagonists for BPD across Israeli (IL) and European (EP) jurisdictions, with earliest priority dating to 2006 and multiple divisional grants through 2021. These patents cover TGF-β antagonist administration both prenatally (directly to the fetus in utero or indirectly via maternal dosing) and postnatally to treat premature infants at risk of BPD. The mechanistic rationale is that excess TGF-β signaling impairs terminal lung alveolar development in the injured premature lung—a premise supported by the broader literature identifying TGF-β as an upstream activator of canonical WNT signaling and an inhibitor of PPARγ, collectively impeding alveolar maturation.

No clinical trial data for TGF-β antagonism in BPD have been retrieved. The approach represents the most commercially defined IP position in the dataset but has not yet generated a clinical translation signal. Research standards from bodies such as EMA and FDA for neonatal drug development create additional regulatory complexity that may contribute to the gap between patent protection and clinical investigation in this indication.

Managing BPD-Associated Pulmonary Hypertension: Current Pharmacotherapy

BPD-associated pulmonary hypertension (BPD-PH) affects approximately 25–40% of severe BPD cases and represents a distinct and serious complication requiring targeted vasoactive therapy. The most robust clinical pharmacotherapy dataset in the retrieved literature comes from Columbia University Irving Medical Center: a cohort of 101 BPD-PH patients treated between 2005 and 2016, in which 98% received sildenafil as first-line therapy.

Sildenafil (a phosphodiesterase-5 inhibitor) acts as first-line therapy, with endothelin receptor antagonists (bosentan) and prostacyclin analogs (iloprost, epoprostenol, treprostinil) deployed in refractory or combination settings. Multi-omic tracheal aspirate analysis—combining miRNA PCR arrays, RNA sequencing, and proteomics—reported by Penn State Health (2022) signals a future trajectory toward biomarker-guided patient stratification for BPD-PH, potentially enabling more targeted pharmacotherapy selection. Emerging FGF pathway research from Justus-Liebig-University Giessen specifically interrogates FGF signaling contributions to pulmonary vascular development as a novel mechanistic angle for BPD-PH beyond the three established drug classes. Patent databases tracked by WIPO indicate that vascular remodeling in neonatal pulmonary hypertension remains an active area of IP generation globally.

Emerging Directions: Cell-Free Exosomes, AntimiR Therapy, and Novel Small Molecules

Several emerging directions in the BPD pipeline aim to address the limitations of current approaches—most notably the manufacturing complexity of live-cell MSC therapy, the developmental stage gap for growth factor approaches, and the need for more targeted molecular interventions. Four directions stand out as having specific preclinical evidence in the retrieved literature.

Cell-Free MSC-Derived Exosomes

The Harvard Medical School review (2019) frames MSC-derived exosomes (MEx) as a compelling therapeutic alternative to direct MSC transplantation, citing three practical advantages: manufacturing standardization, cryostability, and avoidance of cell-viability attrition during processing. This transition from cell therapy to cell-free product represents a broader trend in regenerative medicine documented by researchers at institutions including those publishing in Nature journals. The 2012 Children’s Hospital Boston/Harvard Medical School demonstration that a single intravenous dose of MSC-derived conditioned media reversed hyperoxia-induced BPD and pulmonary hypertension in a rodent model—normalizing alveolar injury and blood vessel density—provides the mechanistic foundation for this direction.

Intranasal MSC Delivery

The University of Texas Health Science Center San Antonio (2019) demonstrated feasibility of intranasal hUC-MSC delivery restoring lung alveolarization and vascularization in experimental BPD. This non-invasive route could circumvent the procedural risks of intratracheal instillation in fragile preterm infants, representing a meaningful safety and accessibility advantage over current intratracheal delivery protocols.

AntimiR Therapy Targeting miR-34a/PDGFRα

PDGFRα-expressing myofibroblasts are identified as critical for proper alveolarization, and the miR-34a/PDGFRα interaction is described as a validated causal actor in arrested lung development. In vivo use of a target site blocker in a murine BPD model (University of Giessen and Marburg Lung Center, 2019) partially corrected alveologenesis defects, signaling a potential RNA therapeutic strategy for arrested lung development. Bone marrow MSCs transfected with miR-206 for BPD treatment in neonatal mice (Beijing BaYi Children’s Hospital, 2019) represent a convergent approach combining MSC delivery with genetic augmentation of anti-fibrotic signaling.

AVR-48: A Novel Small Molecule

The chitin-derived small molecule AVR-48 (Duke University Medical Center, 2021) showed safety and prophylactic efficacy in a neonatal mouse BPD/PH model. This represents the only retrieved small molecule candidate with specific preclinical evidence in BPD, distinct from the established pharmacotherapy classes. Recombinant human surfactant protein D (rhSP-D), identified by researchers at the University of Cincinnati College of Medicine (2021), represents a further immunomodulatory direction acting via TLR4 pathway suppression and reduced pro-inflammatory mediator release.